The specific objective of this application is to continue to make available cutting-edge clinical cancer treatment and cancer control research protocols in our area. A primary goal of the Sioux Community Cancer Consortium (SCCC) is to achieve approximately 130 credits for clinical cancer treatment protocols and greater than 200 credits for cancer control research protocols per year. These are realistic accrual goals based on the past accomplishments of the SCCC. Additionally, the SCCC will educate the primary care physicians and the general public in early detection and prevention to promote wellness. The SCCC will also focus on reaching the minority populations in the underserved areas. The SCCC is a two component, one affiliate, community based clinical cancer research organization. The SCCC was founded in 1983 and has been a continuing community clinical oncology program of the National Cancer Institute (NCI) since that time. The two major components of SCCC are in Sioux Falls, South Dakota, and Sioux City, Iowa. The Sioux Falls, South Dakota component has an affiliate in Fort Collins, Colorado. The two component sites are separated by a mere 90 miles on Interstate 29 in the rural Midwest. The SCCC is the major source of clinical cancer research sponsored by the NCI in Sioux Falls, South Dakota and Sioux City, Iowa. The geographic catchment areas for the SCCC cover approximately 105,000 square miles in Southeastern South Dakota, Southwestern Minnesota, Northwestern Iowa and Northeastern Nebraska. The Fort Collins affiliate covers an approximate radius of 35,000 square miles. The primary research base for the SCCC will remain the North Central Cancer Treatment Group (NCCTG). The SCCC is a secondary CCOP of the Eastern Cooperative Oncology Group (ECOG). The SCCC is a member of the National Surgical Adjuvant Breast and Bowel Project (NSABP) and participates in their treatment and the STAR trials. The SCCC participates in the SELECT trial through the Southwest Oncology Group (SWOG). In Sioux Falls, South Dakota, two of the pediatric hematology/oncologists participate in the Children's Oncology Group and are members of the SCCC. The SCCC research is carried out by research teams dedicated to excellent protocol management and record keeping. The SCCC consists of 26 core investigators in medical oncology, radiology oncology, pediatric oncology, gynecology oncology, and surgery. There are a number of supporting physicians and/or investigators in the surgery, pathology, and medical practice arena.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1-SRRB-E (J1))
Program Officer
Whitman, Cynthia B
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Sanford Clinic
Sioux Falls
United States
Zip Code
Barton, Debra L; Sloan, Jeff A; Shuster, Lynne T et al. (2018) Evaluating the efficacy of vaginal dehydroepiandosterone for vaginal symptoms in postmenopausal cancer survivors: NCCTG N10C1 (Alliance). Support Care Cancer 26:643-650
Schild, Steven E; Hillman, Shauna L; Tan, Angelina D et al. (2017) Long-Term Results of a Trial of Concurrent Chemotherapy and Escalating Doses of Radiation for Unresectable Non-Small Cell Lung Cancer: NCCTG N0028 (Alliance). J Thorac Oncol 12:697-703
Bhatia, Aarti K; Lee, Ju-Whei; Pinto, Harlan A et al. (2017) Double-blind, randomized phase 3 trial of low-dose 13-cis retinoic acid in the prevention of second primaries in head and neck cancer: Long-term follow-up of a trial of the Eastern Cooperative Oncology Group-ACRIN Cancer Research Group (C0590). Cancer 123:4653-4662
Liu, Xiaonan; Li, Jing; Schild, Steven E et al. (2017) Statins and Metformin Use Is Associated with Lower PSA Levels in Prostate Cancer Patients Presenting for Radiation Therapy. J Cancer Ther 8:73-85
Pachman, Deirdre R; Qin, Rui; Seisler, Drew et al. (2016) Comparison of oxaliplatin and paclitaxel-induced neuropathy (Alliance A151505). Support Care Cancer 24:5059-5068
Neal, Joel W; Dahlberg, Suzanne E; Wakelee, Heather A et al. (2016) Erlotinib, cabozantinib, or erlotinib plus cabozantinib as second-line or third-line treatment of patients with EGFR wild-type advanced non-small-cell lung cancer (ECOG-ACRIN 1512): a randomised, controlled, open-label, multicentre, phase 2 trial. Lancet Oncol 17:1661-1671
Liu, Xiaonan; Li, Jing; Wu, Teresa et al. (2016) Patient Specific Characteristics Are an Important Factor That Determines the Risk of Acute Grade ? 2 Rectal Toxicity in Patients Treated for Prostate Cancer with IMRT and Daily Image Guidance Based on Implanted Gold Markers. OMICS J Radiol 5:
Schneider, Bryan P; O'Neill, Anne; Shen, Fei et al. (2015) Pilot trial of paclitaxel-trastuzumab adjuvant therapy for early stage breast cancer: a trial of the ECOG-ACRIN cancer research group (E2198). Br J Cancer 113:1651-7
Liu, Heshan; Tan, Angelina D; Qin, Rui et al. (2015) Comparing and Validating Simple Measures of Patient-Reported Peripheral Neuropathy for Oncology Clinical Trials: NCCTG N0897 (Alliance) A Pooled Analysis of 2440 Patients. SOJ Anesthesiol Pain Manag 2:
Wagner-Johnston, Nina D; Sloan, Jeff A; Liu, Heshan et al. (2015) 5-year follow-up of a randomized controlled trial of immediate versus delayed zoledronic acid for the prevention of bone loss in postmenopausal women with breast cancer starting letrozole after tamoxifen: N03CC (Alliance) trial. Cancer 121:2537-43

Showing the most recent 10 out of 72 publications